枯草杆菌肠球菌二联活菌胶囊对非酒精性脂肪性肝炎患者血清内毒素水平的影响

doi:10.3969/j.issn.1672-5069.2012.02.007

Abstract

Abstract: Objective To investigate the effect of microecological products capsule containing bacillus subtilis and enterococcus（Medilac-S） on the alteration of intestinal permeability and levels of serum endotoxin in patients with nonalcoholic steatohepatitis（NASH）. Methods Thirty healthy adults and sixty patients with NASH were included in this study.Their serum endotoxin,diamine oxidase, D-lactate and ALT levels were measured respectively.The patients with NASH were treated with Medilac-S for 4 weeks. Results Compared with control,the serum endotoxin,diamine oxidase,and D-lactate levels in patients with NASH increased [143.60±21.41EU/l vs 109.78±17.81EU/l（t=7.71,P<0.01）;2.6±0.47U/ml vs 2.3±0.48U/ml（t=2.24,P<0.05）; and 6.1±1.05mg/l vs 5.3±0.97mg/l（t=4.89,P<0.01）,respectively];after four week treatment with Medilac-S,the serum endotoxin,diamine oxidase,D-lactate and ALT levels decreased remarkably. Conclusions Medilac-S could effectively decrease intestinal permeability and levels of serum endotoxin and ALT in patients with NASH.

Key words: NASH, Intestinal permeability, Microecological products, Bacillus subtilis, Enterococcus, Endotoxin

Yang Linhui, Guo Zhaoyou, Cao Ming, et al.. Effect of capsule containing bacillus subtilis and enterococcus on levels of serum endotoxin in patients with NASH[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2012, 15(2): 101-103.

References

[1] Peter LM. Non-alcoholic steatohepatitis. Eur J Gastroenterol Hepatol,2004,16（11）:1079-1085.
[2] Bugianesi E,Leone N,Vanni E, et al. Expanding the natural history of nonalcoholic steatohepatitis:from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology,2002,123（1）:134-140.
[3] 赵龙凤,贾军梅,韩德五. 肠源性内毒素血症在非酒精性脂肪性肝炎发病中的作用. 中华肝脏病杂志,2004,12（10）:632-632.
[4] Wigg AJ,Roberts-Thomson IC,Dymock RB,et al. The role of small intestinal bacterial overgrowth,intestinal permeability,endotoxaemia,and tumor necrosis factor[alpha] in the pathogenesis of non-alcoholic steatohepatitis. Gut,2001,48（20）:206-211.
[5] Ester V,Elisabetta B. The gut-liver axis in nonalcoholic fatty liver disease:Another pathway to insulin resistance. Hepatology, 2009,49（6）:1791-1793.
[6] 中华医学会肝病学分会脂肪肝与酒精性肝病学组. 非酒精性脂肪性肝病诊疗指南. 中华肝脏病杂志,2010,18（3）：163-166.
[7] 何桂珍.肠道通透性测定及临床意义.中华胃肠外科杂志, 2011,14（3）：226-228.
[8] 夏阳,秦环龙. 肠道屏障功能的临床评估方法. 中国实用外科杂志,2008,28（11）:1006-1008
[9] Han DW. Intestinal endotoxemia as a pathogenetic mechanism in liver failure. World J Gastroenterol,2002,8（6）:961-965.
[10] Markel TA,Crisostomo PR,Wairiuko GM,et a1. Cytokinesin necrotizing enterocolitis.Shock,2006,25（4）:329-337.
[11] Yee SB,Harkema JR,Ganey PE,et a1. The coagulation system contributes to synergistic liver injury from exposure to monocrotaline and bacterial lipopolysaccharide. Toxicol Sci,2003:74（2）:457-469.
[12] Hirose M,Nishikawa M,Qian W,et a1. Mannose-conjugated alendronate selectively depletes Kupffer cells and inhibits endotoxemic shock in the mice. Hepatol Res,2006,36（1）:3-10.
[13] Higuchi Y,Kawakami S,Yamashita F,et a1. The potential role of fucosylated cationic liposome/NFkaPPaB decoy complexes in the treatment of cytokine-related liver disease. Biomaterials,2007,28（26）:532-539.
[14] Hart AL,Stagg AJ,Frame M,et al.The role of the gut flora in health and disease and its modification as therapy. Aliment Pharmacol Ther,2002,16（8）:1383-1393.
[15] 潘莉,韩真.脂肪细胞因子在非酒精性脂肪肝发病机制中的作用. 实用肝脏病杂志,2010,13（2）：151-153.
[16] 徐正婕,范建高,王国良,等. 小剂量内毒素致非酒精性脂肪性肝炎大鼠急性肝功能衰竭. 中华肝脏病杂志,2004,12（4）：244-245.
[17] Kim YG,Moon JT,Lae KM,et al. The efects of probioties on symptoms of irritable bowel syndrome. Korean J Gastroenteml,2006,47（6）：413-419.
[18] 牟方宏,胡伏莲. 又一新的微生态制剂—美常安.临床医学杂志,2004,2（5）：60.
[19] 袁杰利,傅晓丽,文妹,等. 屎肠球菌活菌制剂的研究. 中国微生态学杂志,2003,15（1）：20-21.

Effect of capsule containing bacillus subtilis and enterococcus on levels of serum endotoxin in patients with NASH

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 8

Recommended Articles

Metrics

Comments

[1]	Liu Yanghe, Long Dengyi, Bei Zheng, et al. Efficacy of bacillus subtilis duplex and polyene phosphatidylcholine combination in treatments of patients with nonalcoholic fatty liver diseases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(4): 573-576.
[2]	Chen Guangyao, Han Ji’ao, Zhou Dongxiao. Small intestinal bacterial overgrowth and TLR4 expression on the surface of peripheral blood mononuclear cells in patients with liver cirrhosis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(6): 728-731.
[3]	Liu Xingtao. Systemic inflammatory response syndrome and serum endotoxin levels in patients with acute-on-chronic hepatitis B liver failure [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(6): 758-759.
[4]	You Na, Zhu Jin, Wang Maorong.. Roles of Kupffer cells in liver injuries [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(5): 633-636.
[5]	Dai Liejun,Pang Hong，Huang Tiejun. Serum concentration of soluble heat shock protein and its correlation to intestinal permeability in patients with liver cirrhosis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(5): 546-547.
[6]	Guo Yuening，Wang Liguo，Wang Xiazhen，et al.. Changes of serum cytokines and pulmonary intravascular macrophages in rats with hepatopulmonary syndrome [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2014, 17(2): 176-179.
[7]	Nie Jiao，Li Xin， Xu Youqing.. The effect of endotoxin on intestinal mucous injury in rats with alcoholic liver disease [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2012, 15(3): 206-208.
[8]	DING Wenjin，DUAN Xiaoyan，FAN Jiangao. The efficacy of ω-3 unsaturated fatty acid on NASH rats [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2011, 14(1): 15-17.